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Background
Optimal dosing of recombinant tissue-type plasminogen 
activator (rt-PA) is important in treating pulmonary 
thromboembolism (PTE).
Methods
Objective: Th e aim of this study was to compare the 
eﬃ  cacy and safety of a 50 mg/2 h rt-PA regimen with a 
100 mg/2 h rt-PA regimen in patients with acute PTE.
Design: A prospective, randomized, open label trial.
Setting: A multicenter trial in China.
Subjects: 118 patients with acute PTE and either hemo-
dynamic instability or massive pulmonary artery 
obstruction.
Intervention: Patients were randomly assigned to receive 
a treatment regimen of either rt-PA at 50 mg/2 h (n= 65) 
or 100 mg/2 h (n= 53).
Outcomes: Th e eﬃ  cacy was determined by observing the 
improvements of right ventricular dysfunctions (RVDs) 
on echocardiograms, lung perfusion defects on venti la-
tion perfusion lung scans, and pulmonary artery obstruc-
tions on CT angiograms. Th e adverse events, including 
death, bleeding, and PTE recurrence, was also evaluated.
Results
Progressive improvements in RVDs, lung perfusion 
defects, and pulmonary artery obstructions were found 
to be similar in both treatment groups. Th is is true for 
patients with either hemodynamic instability or massive 
pulmonary artery obstruction. Th ree (6%) patients in the 
rt-PA 100 mg/2 h group and one (2%) in the rt-PA 
50  mg/2 h group died as the result of either PTE or 
bleeding. Importantly, the 50 mg/2 h rt-PA regimen 
resulted in less bleeding tendency than the 100 mg/2 h 
regimen (3% vs. 10%), especially in patients with a body 
weight, 65 kg (14.8% vs. 41.2%, P = 0.049). No fatal recur-
rent PTE was found in either group.
Conclusions
Compared with the 100 mg/2 h regimen, the 50 mg/2 h 
rt-PA regimen exhibits similar eﬃ  cacy and perhaps 
better safety in patients with acute PTE. Th ese ﬁ ndings 
support the notion that optimizing rt-PA dosing is 
worthwhile when treating patients with PTE.
Commentary
Acute pulmonary thromboembolism (PTE) is a disease 
with variable clinical severity that can range from no 
symptoms to severe hypoxia, hypotension, right heart 
failure and death. Th rombolytic therapy is known to im-
prove physiologic parameters and right heart function in 
PTE. Th is therapy is routinely used in patients who have 
hemodynamic instability. However, its role in patients with 
large PTE in the absence of hemodynamic in stability, 
particularly in the subset with right ventricular strain, is 
controversial. Few large randomized clinical trials(RCTs) 
have been conducted to assess eﬃ  cacy of thrombolytic 
therapy for diﬀ erent subgroups of patients with PTE and 
to compare diﬀ erent dosing regimens, Current recommen-
dations are largely based on results of observational studies 
or meta-analyses of small RCT [1-3].
Recombinant tissue-type plasminogen activator (rt-PA) 
is currently the most commonly used thrombolytic 
therapy for PTE. Similar to most thrombolytic agents, © 2010 BioMed Central Ltd
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rt-PA carries a signiﬁ cant dose-dependent risk of bleed-
ing, and it is the most common adverse eﬀ ect associated 
with thrombolytic therapy for PTE. In a retrospective 
analysis of 104 patients with PTE who receive rt-PA, 20 
patients (19%) had major bleeding [4]. Th e most devastat-
ing complication is intracranial bleed and it occurs in up 
to 3% of patients. Th us, optimal dosing to maximize bene-
ﬁ ts and minimize bleeding complications is important.
Few studies had compared diﬀ erent thrombolytic doses 
for PTE [5,6]. For example, Goldhaber and colleagues 
com pared 0.6  mg/kg over 15  min (maximum dose of 
50 mg) and 100 mg over 2 hours in 90 patients. No signi-
ﬁ  cant diﬀ er ences were detected between both groups 
with regards to bleed ing complications and eﬃ  cacy, as 
measured by perfu sion lung scans, pulmonary angio-
grams and echo cardiograms.
With this background, Wang and colleagues conducted 
a randomized, multicenter study to compare low vs. high 
dose rt-PA in treatment of acute massive PTE [7]. 
Patients were included if they were 18 years or older and 
present with symptoms of acute PTE within 15 days of 
enrolment. Th is study enrolled patients with large PTE, 
as evidence by hemodynamic instability (systolic blood 
pressure [BP] <90 mmHg or drop in systolic BP of at least 
40mmHg for at least 15 minutes), cardiogenic shock or 
those with anatomically massive PTE (CT scan showed 
occlusion of more than 2 lobar arteries, or V/Q scan 
showed occlusion >7 segments combined with right ven-
tricular dysfunction on echocardiography). For sample 
size calculation, the authors calculated the number of 
patient needed to demonstrate a reduction in the CT 
obstruction score by 10 points. A total number of 118 
patients were enrolled (65 in the low dose and 53 in the 
high dose group). Th e primary endpoints were eﬃ  cacy of 
thrombolysis, as measured by improvement in right 
ventricular function by echocardiogram, improve ment in 
perfusion by V/Q scan and improvement in CT obstruc-
tion score. No diﬀ erences in eﬃ  cacy were ob served 
between the two groups. Secondary endpoints were 
safety endpoints, including bleeding risk. Bleeding events 
were categorized into major and minor events. Major 
events included bleeding leading to death, caused a drop 
in hemoglobin >2 g/dl, or required transfusion more than 
400 cc blood and intra cranial hemorrhage. Minor events 
included bleeding that led to a drop of less than 2 g/dl in 
hemoglobin. Other secondary endpoints were recurrence 
of PTE and death. Although bleeding risk was no diﬀ er-
ent, in subgroup analysis stratiﬁ ed by body weight, the 
risk of total number of bleeding episodes were less with 
the low dose regimen than in the high dose regimen, 
especially in patients with body weight <65 kg (14.8% in 
the low dose vs. 41.2% in the high dose group, P = 0.049) 
or BMI <24 (8.7% in the low dose vs. 42.9% in the high 
dose group, P = 0.014).
To date, this study is the largest one to compare 
diﬀ erent dosing regimens of rt-PA for acute PTE. Th e 
subgroup analysis according to body weight suggests that 
using weight-based dosing may reduce bleeding 
complications. However the study has limitations. Th e 
authors chose a surrogate endpoint and its clinical 
signiﬁ cance is unclear. For example, it is diﬃ  cult to 
estimate the clinical signiﬁ cance of a 1 point decrease in 
the CT obstruction score. Although mortality would be 
an important outcome measure, it was a secondary 
outcome in this study and there were only a few deaths.
Th is study highlights the importance of considering 
alternative study designs to compare diﬀ erent dose 
regimens of thrombolytic therapy for PTE. For instance, 
lower dose may have similar eﬃ  cacy but lower bleeding 
complications, thus such studies should be designed as 
non-inferiority or equivalence trial, with the hypothesis 
that clinical eﬃ  cacy would be similar but bleeding risk 
would be lower.
In conclusion, this trial did not prove diﬀ erences in 
eﬃ  cacy between low dose and high dose rt-PA regimens. 
Th e secondary analyses showing that lower dose of rt-PA 
may lower the risk of bleeding suggest a need for 
additional studies to use weight-based regimens to 
reduce risk of bleeding.
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